ATSN-101 Gene Therapy Reports Positive Data in Phase 1/2 Trial; ATSN-101 was well tolerated 12 months after treatment and demonstrated on average, a 100-fold improvement in vision, with some improved by 10,000-fold.

Media coverage

• Title	ATSN-101 Gene Therapy Reports Positive Data in Phase 1/2 Trial; ATSN-101 was well tolerated 12 months after treatment and demonstrated on average, a 100-fold improvement in vision, with some improved by 10,000-fold.
  Media name/outlet	Consultant Live
  Country/Territory	United States
  Date	10/09/24
  Persons	Niamh Moore

• Title	ATSN-101 Gene Therapy Reports Positive Data in Phase 1/2 Trial
  Media name/outlet	HCP Live
  Country/Territory	United States
  Date	10/09/24
  Persons	Niamh Moore